Usefulness of Ezetimibe Versus Evolocumab as Add-On Therapy for Secondary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus

Evolocumab and ezetimibe, were both proven to significantly reduce the incidence of major adverse cardiovascular events (MACE), in type 2 diabetes patients with atherosclerotic cardiovascular disease and low-density lipoprotein (LDL) cholesterol >70 mg/dl despite statin therapy. Providing evolocu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American journal of cardiology 2019-04, Vol.123 (8), p.1273-1276
Hauptverfasser:	Arbel, Ronen, Hammerman, Ariel, Azuri, Joseph
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Angina pectoris Antibodies, Monoclonal, Humanized - therapeutic use Anticholesteremic Agents - therapeutic use Arteriosclerosis Atherosclerosis Cardiovascular diseases Cardiovascular Diseases - epidemiology Cardiovascular Diseases - etiology Cardiovascular Diseases - prevention & control Cholesterol Clinical trials Confidence intervals Cost analysis Cost engineering Costs Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Ezetimibe - therapeutic use Female Health care Heart attacks Humans Incidence Israel - epidemiology Low density lipoprotein Male Middle Aged Monoclonal antibodies Patients Prevention Risk Factors Secondary Prevention - methods Sensitivity analysis Simulation Stroke Survival Rate - trends Therapy Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!